Acute Myocardial Infarction While Using the Nicotine Patch

Ottervanger, Jan Paul; Festen, Jeroen M.; Vries, Arie G. de; Stricker, Bruno H. Ch.

doi:10.1378/chest.107.6.1765

Cited by 32 publications

(18 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cigarette smoking has long been known to promote atherosclerosis, with an increased risk of sudden death,75 myocardial infarction76 77 and stroke 78. The use of nicotine therapies such as transdermal patches, inhalators and gum as well as the common use of chewing tobacco in some sports has also been associated with an increased cardiovascular event risk 79 80. Again, much of these data have come from case study and anecdotal data, with larger studies not observing a significant increase in risk of cardiovascular events 81.…”

Section: Stimulants—cocaine and Othersmentioning

confidence: 99%

Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician

et al. 2012

View full text Add to dashboard Cite

The use of performance-enhancing and social drugs by athletes raises a number of ethical and health concerns. The World Anti-Doping Agency was constituted to address both of these issues as well as publishing a list of, and testing for, banned substances in athletes. Despite continuing methodological developments to detect drug use and associated punishments for positive dope tests, there are still many athletes who choose to use performance and image enhancing drugs. Of primary concern to this review are the health consequences of drug use by athletes. For such a large topic we must put in place delimitations. Specifically, we will address current knowledge, controversies and emerging evidence in relation to cardiovascular (CV) health of athletes taking drugs. Further, we delimit our discussion to the CV consequences of anabolic steroids and stimulant (including amphetamines and cocaine) use. These drugs are reported in the majority of adverse findings in athlete drug screenings and thus are more likely to be relevant to the healthcare professionals responsible for the wellbeing of athletes. In detailing CV health issues related to anabolic steroid and stimulant abuse by athletes we critique current research evidence, present exemplar case studies and suggest important avenues for on-going research. Specifically we prompt the need for awareness of clinical staff when assessing the potential CV consequences of drug use in athletes.

show abstract

Section: Stimulants—cocaine and Othersmentioning

confidence: 99%

Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician

et al. 2012

View full text Add to dashboard Cite

show abstract

“…However, the safety of chronic nicotine replacement has not been fully established. Nicotine may contribute through catecholamine release to the pathophysiology of acute ischaemic events (Benowitz 1991), and there are reports of cardiovascular events like myocardial infarction (Ottervanger et al 1995), stroke (Pierce 1994), and cerebral haemorrhage (Riche et al 1995) associated with the use of nicotine substitution.…”

Section: Introductionmentioning

confidence: 99%

Effects of smoking cessation and nicotine substitution on systemic eicosanoid production in man

Saareks

Ylitalo

Alanko

et al. 2001

Naunyn-Schmiedeberg's Archives of Pharmacology

View full text Add to dashboard Cite

This study investigated the effects of smoking cessation with and without nicotine substitution on the excretion of major urinary metabolites of thromboxane A2 and prostacyclin, 11-dehydrothromboxane B2 and 2,3-dinor-6-ketoprostaglandin F1alpha, respectively, as well as on the excretion of leukotriene E4 in man. Urine samples were obtained from 20 healthy non-smoking controls and from 60 healthy smoking volunteers before, and 3, 7 and 14 days after smoking cessation. Fifteen smokers quit smoking without nicotine substitution, 15 used nicotine chewing gum and 30 used nicotine patches as a substitution therapy. Urinary thiocyanate as well as cotinine and trans-3'-hydroxycotinine excretions were used as compliance and nicotine substitution indicators. 11-Dehydrothromboxane B2, 2,3-dinor-6-ketoprostaglandin F1alpha and leukotriene E4 excretion was about two, three and five times higher in smokers than in controls, respectively. Three days after smoking cessation without nicotine substitution, 11-dehydrothromboxane B2 and 2,3-dinor-6-ketoprostaglandin F1alpha levels were lowered to 75% (P<0.01) and 80% (P<0.05) of the initial values, and after 14 days to 50% (P<0.01) and 60% (P<0.05), respectively. In 3 days leukotriene E4 excretion was dropped to 70% of the initial value (P<0.05), but no further decrease was observed during the study. In individuals using nicotine chewing gum or nicotine patches no significant changes were observed in the analytes during the 2-week follow-up. The increased systemic eicosanoid synthesis observed in smokers may be involved in the harmful cardiovascular effects of smoking. The fact that eicosanoid production remains at pre-cessation level in volunteers who quit smoking but use nicotine substitution may be involved in the risk of cardiovascular complications reported during nicotine replacement therapy.

show abstract

“…Anecdotally, adverse CVD events, including acute myocardial infarction (MI), coronary vasospasm, aortic dissection, vasculitis, intracranial vasospasm, and intracerebral hemorrhage, have been demonstrated in patients with NRT [25][26][27][28][29][30][31][32]. It is important to keep in mind that smokers, irrespective of NRT usage, have an increased risk for all CVD events compared with nonsmokers [1,4].…”

Section: Nicotine Replacement Therapymentioning

confidence: 99%

“…A recent network meta-analysis of 21 RCTs involving NRT [40••] demonstrated a statistically significant association of lower-risk events like arrhythmia and tachycardia with the use of NRT, which are well-documented benign side effects [25,28,32,35]. These occurred primarily in studies with longer periods of follow-up.…”

Section: Nrt In Smokers With Known Cvdmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies

et al. 2014

View full text Add to dashboard Cite

Smoking continues to be the leading cause of preventable deaths in the USA, accounting for one in every five deaths every year, and cardiovascular (CV) disease remains the leading cause of those deaths. Hence, there is increasing awareness to quit smoking among the public and counseling plays an important role in smoking cessation. There are different pharmacological methods to help quit smoking that includes nicotine replacement products available over the counter, including patch, gum, and lozenges, to prescription medications, such as bupropion and varenicline. There have been reports of both nonserious and serious adverse CV events associated with the use of these different pharmacological methods, especially varenicline, which has been gaining media attention recently. Therefore, we systematically reviewed the various pharmacotherapies used in smoking cessation and analyzed the evidence behind these CV events reported with these therapeutic agents.

show abstract

Acute Myocardial Infarction While Using the Nicotine Patch

Cited by 32 publications

References 10 publications

Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician

Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician

Effects of smoking cessation and nicotine substitution on systemic eicosanoid production in man

Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies

Contact Info

Product

Resources

About